📰 Relapsed Refractory News
Relapsed Refractory News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Relapsed Refractory. Real-time updates on events, politics, business and more.
April 13, 2023
Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.
November 3, 2022
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts will be presented at the American Society of Hematology (ASH) Annual...
November 3, 2022
Key data includes results for intravenous administration of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients DUBLIN
November 4, 2021
Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA
November 4, 2021
Two abstracts will be presented in a pre-recorded poster presentation and oral session Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD)
November 4, 2021
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...
November 4, 2021
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...